Abstract:
PROBLEM TO BE SOLVED: To provide a treating method for increasing the content of flavonoid in plants and to provide a therapeutic composition, a health food or a cosmetic each containing a plant obtained by applying the treatment or its extract. SOLUTION: The treating method comprises treating plants with a compound represented by formula (I). An extract, juice, wine or press cake, in which contents of flavonoid and the other phenolic component are increased and these components are qualitatively modified, are each obtained from a grape fruit of a red grape variety which is a grape plant in which the above treatment is applied. COPYRIGHT: (C)2006,JPO&NCIPI
Abstract:
The invention relates to the use of at least one lipoic acid, a physiologically acceptable derivative or salt thereof, at least one carnitine, a physiologically acceptable derivative or salt thereof, and at least one creatine, and a physiologically acceptable derivative or salt thereof, for supplementing food, in functional foods and for therapeutic purposes, i.e. especially for treating certain disorders associated with oxidative processes. The invention also relates to agents having a corresponding combination of active ingredients, and agents in the form of commercial packages having corresponding combination preparations or monopreparations for combined use.
Abstract:
The invention relates to food, dietary or pharmaceutical preparations, containing conjugated trans/cis octadecatrienic acids and methods for production thereof. Said preparations preferably contain calendulic acid. The invention further relates to the use of the preparations for the reduction of dietary uptake in humans and animals and for improved dietary utilisation.
Abstract:
The invention relates to the use of stable ammonium a-liponate salts for the treatment of a series of disease states, in particular, diabetic disorders and disorders of diabetic origin. The salts (Lp) (A) are formed from a-liponic acid (Lp) and ammonium compounds (A) of general formula (II) or (III). Further application of the salts are related to the treatment of cardiovascular disorders, neurodegenerative disorders and diseases related to chronic kidney failure and/or dialysis treatment, retinopathies, nephropathies, proteinurias, hyperlipidaemias, hypertriglyceridaemias, hypercholesterinaemias, proliferations of smooth muscle cells in arteries, collagenoses, arthritis, fibromyalgias, kidney stones, inflammation, cancer, amyloidoses, osteoporoses, excess weight and obesity, HIV infections and AIDS, metabolic syndrome, oxidative stress and related diseases and the aging process.
Abstract:
The invention relates to the use of lipoic acids, or a physiologically acceptable derivative or salt thereof, and a compound of formula (I): H3C-(CH2)n1-(CH=CH)n3-(CH2)n2-COOH - wherein n1 and n2 independently have the value of a whole number from 3 to 9, n3 has the value of a whole number from 2 to 6, and the number of carbon atoms amounts to 18, 20 or 22 - or a physiologically acceptable derivative or salt thereof, as food supplements, in functional foods and for therapeutic purposes in the treatment of diabetic disorders. The invention also relates to agents having a corresponding active ingredient combination and to agents in the form of commercial packs having corresponding combination preparations or monopreparations for combined use.
Abstract:
The invention relates to a method for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders which comprises administering a therapeutically active amount of at least one compound selected from the group consisting of alpha -tocotrienol, beta -tocotrienol, gamma -tocotrienol and delta -tocotrienol and their derivatives.
Abstract:
Compositions containing folic acid in combination with 5-methyltetrahydrofolic acid are disclosed, as well as compositions containing folic acid, 5-methyltetrahydrofolic acid and/or 5-methyltetrahydrofolic acid polyglutamate and a dietary component and/or a dietary preparation and the use thereof.
Abstract:
The invention relates to the use of lipoic acid and C1 donors, especially S-adenosylmethionine and/or 5-methyltetrahydrofolate, for treating disorders of the central nervous system. The invention also relates to agents containing a corresponding active substance combination and to agents in the form of commercial packages containing the inventive combination preparations or monopreparations for combined use.